Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germinal center (GC) dependent process. However, clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Seema R., Lundgren, Taran S., Baldwin, Wallace Hunter, Cox, Courtney, Parker, Ernest T., Healey, John F., Jajosky, Ryan P., Zerra, Patricia E., Josephson, Cassandra D., Doering, Christopher B., Stowell, Sean R., Meeks, Shannon L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132091/
https://www.ncbi.nlm.nih.gov/pubmed/35634288
http://dx.doi.org/10.3389/fimmu.2022.880829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132091/
https://www.ncbi.nlm.nih.gov/pubmed/35634288
http://dx.doi.org/10.3389/fimmu.2022.880829

Ejemplares similares